Cambridge Healthtech Institute’s 8th Annual
Late Stage Research Strategy and Operations
RWE for Regulatory Decisions, Market Access and Pharmacovigilance
February 19-20, 2019
Real world evidence solutions have changed the design and execution of peri-approval and post-marketing research. Real time real world data generation, pragmatic trials, and next generation databases open new opportunities for post-marketing research
as well as regulatory and market access needs. Data generated in peri-approval real world data-based studies is essential for multiple stakeholders within and outside pharmaceutical companies, such as regulatory agencies, payers, health care management
organizations, formulary inclusion decision makers, healthcare professionals, and patients. Cambridge Healthtech Institute’s 8th Annual Late Stage Research Strategy and Operations conference is designed
to facilitate knowledge exchange around all aspects of peri-approval studies and major application of their outcomes/generated data.
Final Agenda
Scientific Advisory Board
Cathy
Critchlow, PhD, Vice President, Center for Observational Research, Amgen
Hui Cao,
PhD, Executive Director, Real World Evidence, Global Medical Affairs, Novartis
Pharmaceuticals
Charles Makin,
Global Head, Real World Evidence Strategy, Biogen
Marc Berger,
MD, Chair, Real World Evidence Advisory Committee, SHYFT Analytics
Monday, February 18
9:00 am – 7:15 pm Registration Open (Convention Level)
2:00 – 5:00 pm User Group Meetings
Shared Investigator Platform User Forum
Trifecta Annual User Group Forum
5:00 – 6:15 pm Pre-Conference Plenary Keynote Panel &
Participant Engagement Award (Regency PQ)
6:15 – 7:15 pm SCOPE’s Kick-off Networking Happy Hour Hosted by CHI (Sponsorship Opportunities Available) (Pool Decks)
7:15 pm Close of Day
Tuesday, February 19
7:15 am Registration Open and Morning Coffee (Convention Level)
8:15 Opening Plenary Keynotes
9:35 Grand Opening Coffee Break in the Exhibit Hall (Plaza International Ballroom)
10:35 Chairperson’s Remarks
Charles Makin, Global Head, Real World Evidence Strategy, Biogen
10:40 RWD: Studies for Formulary Decision Making and Health Technology Assessment – A US Perspective
Martin Marciniak, PhD, Vice President, US Medical
Affairs, Customer Engagement, Value, Evidence & Outcomes, GSK
HTA is heavily dependent on real world data (RWD) in part because of its focus on measuring outcomes that extend past that offered by traditional clinical trial data or systematic reviews. RWD, in its many forms (e.g., pragmatic, observational,
social media, other) is increasingly viewed as an important part of this process, particularly outside of the United States. What does this mean for the US, and its nascent HTA infrastructure?
11:10 Considerations for Use of Real World Evidence to Inform Regulatory Decisions
Cathy Critchlow, PhD, Vice President, Center for
Observational Research, Amgen
Real world evidence (RWE) will be increasingly used in regulatory submissions seeking approval for a new indication, label expansion, or new product marketing authorization. The 21st Century Cures Act places additional focus on the use of RWE
in regulatory decision making. While growing availability of data and sophistication of analytic tools have transformed RWE generation, challenges impeding full realization of benefit from RWE involve issues such as data quality and what constitutes
“substantial evidence” when using RWE as supporting or pivotal evidence. Considerations to help ensure the advancement of suitable RWE use cases to enable appropriate impact of RWE in regulatory decision making will be discussed.
11:40 Use of Real World Data (RWD) to Assess Cardiovascular Safety of Prucalopride to Support a New Drug Application in the US
William Spalding, MS, Director, Outcomes
Research-Epidemiology, Shire
Prucalopride belongs to the 5HT4 agonist drug class, and 2 previously approved 5HT4 agonist drugs have been removed from the market for increased risk of adverse cardiovascular (CV) events. Shire, in agreement with the FDA, sponsored a CV
safety study based on RWD from clinical use of prucalopride in European markets where prucalopride has been marketed since 2009. This talk discusses rationale for use of RWD to assess drug safety.
12:10 pm Using Technology to Maximize Patient Choice While Minimizing Burden in Post-Approval Research
Chris Watson, PhD, Director, Product Strategy, Digital Patient Product Management,
ERT
With the rise in importance of prospective patient data capture as part of real-world evidence analysis how can we make it simpler and easier for patients to participate - and remain engaged - in post-approval research? What role does technology
play and how can advances in consumer technology simplify the process for patients, investigators and sponsors?
12:40 Transition to Lunch
12:45 LUNCHEON PRESENTATION: Optimizing Real World Research Design: Methodologic and Regulatory Perspectives
Stuart McCully, PhD, Vice President, Regulatory Advisory Services, Syneos Health
David Thompson, PhD, Senior Vice President, Real World Evidence Advisory, Syneos Health
1:25 SCOPE Turns 10! Champagne and Dessert in the Exhibit Hall (Plaza International Ballroom)
2:05 Chairperson’s Remarks
Hui Cao, PhD, Executive Director, Real World Evidence, Global Medical Affairs, Novartis Pharmaceuticals
2:10 A Practical Paradigm of Using RWE for Seeking Regulatory Decisions in Label Expansion or New Indication
Hui Cao, PhD, Executive Director, Real World Evidence, Global Medical
Affairs, Novartis Pharmaceuticals
21st Century Cure Act required the FDA to provide a framework and guidance for evaluating RWE in the context of drug regulation to support approvals of new indications for previously approved drugs and to support or fulfill post-approval study
requirements. We established a practical paradigm to guide drug projects teams in developing high-quality RWE proposals to the FDA for these two areas.
2:40 Enhancing the Credibility of Real-World Evidence to Expand it Usage by Decision Makers
Marc Berger, MD, Chair, Real World Evidence Advisory Committee, SHYFT Analytics
3:10 Accelerating Clinical Research by Mining and Leveraging Electronic Health Records Data
Todd Johnson, MD, MBA, Senior Vice President, Clinical Research, Optum
We’ve all heard the statistics. Half of all clinical trials miss their timelines. Eleven percent of trial sites don’t enroll a single patient. It can cost $2-3 billion dollars to bring a new drug to market. This is an incredibly
challenging area that is ripe for new ideas and approaches. Optum is now ready to launch a solution that will significantly change the way clinical research is done. It’s called the Digital Research Network and its goal is to combine
EHR data (80+ million lives), leading-edge cloud-based technology, study design expertise and our existing relationships with research-ready provider groups in a way that only Optum can. The result will be an entirely new way to conduct
clinical research that will shorten time to market and reduce the overall cost of clinical research.
3:40 A Dialogue on FDA Draft Framework for Real-World Evidence Programs
Jacqueline Corrigan-Curay, JD, MD, Director, Office of Medical Policy, CDER, FDA
The session is dedicated to a discussion on the FDA Draft Framework for Real-world Evidence Programs that was issued in December, 2018.
Q&A Moderator: Hui Cao, PhD, Executive Director, Real World Evidence, Global Medical Affairs, Novartis Pharmaceuticals
4:10 Find Your Table and Meet Your Moderator
4:15 Interactive Breakout Discussion Groups
Concurrent breakout discussion groups are interactive, guided discussions hosted by a facilitator or set of co-facilitators to discuss key issues presented earlier in the day’s sessions. Delegates will join a table of interest and become
an active part of the discussion. Bring your pharma, biotech, CRO, site, hospital or patient perspective to each of the discussions. To get the most out of this interactive session and format, please come prepared to share examples from
your work, vet some ideas with your peers, be a part of group interrogation and problem solving, and most importantly, participate in active idea sharing.
5:00 Welcome Reception in the Exhibit Hall (Plaza International Ballroom)
6:30 Close of Day
Wednesday, February 20
7:15 am Registration Open (Convention Level)
7:45 BREAKFAST PRESENTATION: ICF Authoring - The Next Evolution of Informed Consent (Regency P)
Eric Delente, Head, Patient Consent, DrugDev, An IQVIA Company
This session will explore how the recent introduction of informed consent form (ICF) authoring systems, including IQVIA ICF Author, have evolved the informed consent process by allowing sponsors and CROs to create, distribute, and track ICFs
from a centralized portal, whether using paper forms or eConsent. It will also explore the features and benefits of these portals, showing why sponsors and CROs should consider adoption.
8:15 Session Break
8:20 Chairperson’s Remarks
Ken Light, Executive Vice President, Corporate Strategy, OmniComm Systems
8:25 Real World Considerations for Using Real World Common Data Models and Rapid Analytics
Guo Li, Director, Real World Evidence (RWE) Analytics, Novartis
Use of real world data (RWD) has evolved over the last several decades to a point where the body of evidence for any research question can easily be addressed across multiple databases with the use common data models (CDMs). These CDMs can
enable rapid insight generation by improving interoperability across different data types and different geographies, but also come with some important practical limitations.
8:55 Using Data and Analytics to Synthesize Real-World Evidence
Victoria Gamerman, Associate Director,
Biostatistics, Head, Health Informatics & Analytics, Boehringer-Ingelheim Pharmaceuticals, Inc.
In this presentation, learn about an integrated approach to understanding real-world evidence needs throughout the medical organization. Two case studies will be highlighted: (1) an observational US-based registry in a rare disease to capture
the real-world patient journey; and (2) a global survey of patients and physicians in a chronic condition. A future outlook on RWD standards and the role of Big Data in RWE generation will be shared.
9:25 Identifying Breast Cancer Stage and Biomarker Status in Administrative Claims Data Using Predictive Modeling
Cynthia de Luise, PhD, Senior Director,
Epidemiology, Worldwide Safety and Regulatory, Pfizer, Inc.
Claims databases lack stage and receptor status to identify cancer populations. From Anthem’s Cancer Care Quality program validation sample, we used regression and machine learning techniques to construct a predictive model to identify
advanced stage ER+/HER2- breast cancer (ASBC) patients. The model (c-statistic=0.93; PPV=91%; Sensitivity=54%) was applied to the HealthCore Integrated Research Database (HIRD) to identify an ASBC cohort. Predictive modeling can identify
cancer stage and receptor status in claims.
9:55 The Role of RWD After Safety Signals are Identified: Analytic Approaches to Refining a Safety Signal
Irene Cosmatos, Senior Research Specialist, Database Analytics Automation, UBC
10:25 Coffee Break in the Exhibit Hall (Plaza International Ballroom)
11:20 Chairperson’s Remarks
Sean Zhao, PhD, Head, US Patient Safety Surveillance, US Medical Affairs, AstraZeneca Pharmaceuticals, Inc.
11:25 Considerations and Challenges Associated with the Implementation of an Integrated Value-Based Pharmaceutical Data and Evidence Strategy
Tony Hebden, PhD, Vice President, Health Economics &
Outcomes Research, AbbVie
Pharmaceutical companies have identified the need to define value to key access stakeholders as critical to ensuring appropriate patient access to new medications. This approach requires that companies not only define value in terms of the
classical RCT evidence required to obtain regulatory approval, but also develop new processes, infrastructure and governance to ensure less traditional types of evidence are generated and leveraged appropriately.
11:55 Cross-Company Coordination of Post Marketing Research Efforts
Sean Zhao, PhD, Head, US Patient Safety Surveillance, US Medical
Affairs, AstraZeneca Pharmaceuticals, Inc.
There are many types of post marketing research activities, including clinical trials, patient registries, epidemiology studies, health economic and outcome researches, etc., having been used for multiple purposes, i.e., fulfilling regulatory
post marketing requirements (PMRs), supporting in risk management activities, closing clinical evidence gaps, generating real life clinical evidences in supporting formulary decisions, etc. It is important to strategically plan and implement
these studies and activities through a cross-company coordination. The presentation will discuss how to involve cross-company functions in post marketing research activities and when a post marketing research activity’s scientific
purposes can be combined with commercial goals and when they should be separated.
12:25 pm Transition to Lunch
12:30 BRIDGING LUNCHEON PRESENTATION: Sharper Images: How Rollover Studies Can Mitigate Post-Market Study Commitments
Meg Richards, PhD, MPH, Executive Director, Scientific Affairs, Real World Solutions, PRA Health Sciences
Over the past decade, the FDA has increasingly approved new products based on fewer and shorter trials. This reflects a lifecycle evaluation approach, which stresses continued monitoring of safety and effectiveness after the product has been
marketed. Sponsors can be assigned numerous post-market commitments whose delay may result in real-world safety and effectiveness challenges. Properly designed rollover studies can provide a wealth of information about the product well
in advance of marketing.
1:10 Coffee and Dessert Break in the Exhibit Hall (Plaza International Ballroom)
2:10 Close of Conference